Close-up of varied blue puzzle pieces scattered randomly on a white surface.

July’s HD news recap: what did we learn this month?

July was a busy month for Huntington’s disease research and news, with both disappointing announcements and encouraging research. So, what’s relevant to our HD community here in Australia? And what did we learn this past month that gives us hope for the future?

Read on to learn some of the significant news around Huntington’s that occurred in July.

Roche ends two clinical programs

Roche made a disappointing announcement that it would end the development of both the GENERATION HD2 study investigating tominersen and the POINT-HD study, investigating RG6496.

We understand how disappointing this news is for the Australian families who participated in the trials, and for everyone who awaited positive outcomes. However, both studies provided researchers with valuable information that can guide them in the future.

Read more about Roche’s decision here.

New tools allow researchers to better study huntingtin

Scientists are working on a new brain scan that may let them see harmful huntingtin protein clumps in people living with HD. The PET ‘tracer’ binds to specific proteins in the brain, with early tests in mice showing promising results. Next, overseas researchers will aim to measure the new PET in humans, once they establish it’s safe enough to do so.

In other news, researchers made five small protein fragments that stick to huntingtin in different spots, which will make it easier to study in the lab. This work also adds to the evidence that huntingtin usually works closely with another protein called HAP40. Once scientists can learn more about this connection, it will help them better understand how HD develops, and lead toward potential treatment options.

Understanding changes in self-awareness

A recent study in the United States asked people with HD and their partners to rate their symptoms and compare answers. According to findings, a reduced awareness of symptoms in the individual compared to their partner was reported at every stage of their HD journey.

The findings from this small study are helpful in showing families that unawareness of symptoms in people with HD isn’t denial or stubbornness. Instead, it’s a genuine shift in the brain system that occurs with Huntington’s.

SKY-0515 expands from Australia to US and Canada

Skyhawk Therapeutics has expanded its global Phase 2/3 FALCON-HD clinical trial of the investigational Huntington’s disease treatment SKY-0515 to the United States, Canada and the United Kingdom, after promising findings in Australian trials.

More than 175 participants have been enrolled across more than 20 sites in over 10 countries, including Australia, with the worldwide study expected to recruit up to 400 additional patients. While early findings are encouraging, SKY-0515 remains an investigational treatment and has not yet been approved for clinical use.

Looking ahead

Although the HD community received some disappointing news in July, it doesn’t mean researchers have given up on huntingtin-lowering treatments. Each study and advancement in clinical tools and methods brings us one step closer to more effective treatments and understanding of HD.

For more news on Huntington’s disease, read our News page. Alternatively, learn more about HD research in Australia here.

Share this article

Similar Posts

View all news